These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22008005)

  • 1. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
    Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
    Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ; Im K; Broome DR
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
    Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
    Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
    J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital.
    Zou Z; Ma L; Li H
    J Magn Reson Imaging; 2009 Dec; 30(6):1309-12. PubMed ID: 19937931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.
    Chen W; Huang SL; Huang CS; Tsai MC; Lai HM; Lui CC; Eng HL; Chang HW; Lee CH; Chuang FR
    Eur J Dermatol; 2009; 19(1):44-9. PubMed ID: 19059824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis: a report of 29 cases.
    Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
    AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
    Starekova J; Bruce RJ; Sadowski EA; Reeder SB
    Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
    J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis: clinical spectrum of disease.
    Mayr M; Burkhalter F; Bongartz G
    J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
    Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of nephrogenic systemic fibrosis in liver transplantation patients.
    Chow DS; Bahrami S; Raman SS; Rotchel S; Sayre JW; Busuttil RW; Lu DS
    AJR Am J Roentgenol; 2011 Sep; 197(3):658-62. PubMed ID: 21862808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
    Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
    Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.